Jump to Main Content

FDA Alerts

Nilotinib Label Update to Include Treatment Discontinuation Recommendations for CML With Sustained Molecular Responses

FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response.
Citations